At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
Enzalutamidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naïve Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Enzalutamide for Prostate Cancer. Completed, enrolled 67 participants across 12 sites in 4 countries.
Detailed Summary
To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesBelgium, Czechia, Denmark, Germany
CollaboratorsMedivation, Inc.
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartMay 2011
Primary CompletionJul 2012
Study CompletionApr 2017
TodayJul 2026
First PostedFeb 23, 2011
Enrollment StartMay 6, 2011
Primary CompletionJul 29, 2012
Study CompletionApr 27, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.4 years ago
Interventions
Enzalutamidedrug
Oral